研究单位：[1]Sinomune Pharmaceutical Co., Ltd[2]The first affiliated hospital of Baotou medical college,Baotou,China[3]Beijing Tongren Hospital,Beijing,China[4]Peking Union Medical College Hospital,Beijing,China[5]The Second Xiangya Hospital of Central South University,Changsha,China[6]Xiangya Hospital Central South University,Changsha,China[7]The second hospital of Dalian medical university,Dalian,China[8]The affiliated hospital of Inner Mongolia Medical University,Hohhot,China[9]The second people's hospital of Huaian,Huai'an,China[10]Jinan central hospital,Jinan,China[11]Shandong province Qianfoshan hospital,Jinan,China[12]Zhongnan Hospital Southeast University,Nanjing,China[13]The people's hospital of Guangxi Zhuang Autonomous Region,Nanning,China[14]Shenzhen people's hospital,Shenzhen,China[15]The third hospital of Hebei medical university,Shijiazhuang,China[16]General Hospital of Tianjin Medical University,Tianjin,China[17]First Affiliated Hospital of Zhengzhou University,Zhengzhou,China[18]Henan provincal people's hospital,Zhengzhou,China[19]Zhengzhou People's Hospital,Zhengzhou,China[20]Zhuzhou Central Hospital,Zhuzhou,China[21]The First Affiliated Hospital of Xinjiang Medical University,Ürümqi,China
研究目的：
To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
